AIM: To investigate the relationship between insulin receptor substrate-2 (IRS-2) G1057D polymorphism and the risk of gastric cancer (GC) in a Chinese population. METHODS: A case-control study with 197 GC patients and 156 age- and sex- matched control subjects was conducted. The genotypes of polymorphism were assessed by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: The genotype frequencies of IRS-2 G1057D polymorphism in cases were obviously different from those in the control group (P = 0.031). Compared with GG genotype carriers, the risk for GC was significantly higher (adjusted odds ratio = 2.32, 95% CI: 1.03-5.23, P = 0.042) in the individuals with the IRS-2 DD genotype. Furthermore, stratified analysis was performed based on age, sex, smoking status and residence, but no significant difference between the two groups was found. In addition, no significant association between genotypes and clinicopathological features was observed either. CONCLUSION: This study demonstrates that IRS-2 G1057D is involved in susceptibility to GC, although further large-sample studies are still needed.
AIM: To investigate the relationship between insulin receptor substrate-2 (IRS-2) G1057D polymorphism and the risk of gastric cancer (GC) in a Chinese population. METHODS: A case-control study with 197 GC patients and 156 age- and sex- matched control subjects was conducted. The genotypes of polymorphism were assessed by polymerase chain reaction-restriction fragment length polymorphism. RESULTS: The genotype frequencies of IRS-2G1057D polymorphism in cases were obviously different from those in the control group (P = 0.031). Compared with GG genotype carriers, the risk for GC was significantly higher (adjusted odds ratio = 2.32, 95% CI: 1.03-5.23, P = 0.042) in the individuals with the IRS-2 DD genotype. Furthermore, stratified analysis was performed based on age, sex, smoking status and residence, but no significant difference between the two groups was found. In addition, no significant association between genotypes and clinicopathological features was observed either. CONCLUSION: This study demonstrates that IRS-2G1057D is involved in susceptibility to GC, although further large-sample studies are still needed.
Authors: A Fritsche; A Madaus; W Renn; O Tschritter; A Teigeler; M Weisser; E Maerker; F Machicao; H Häring; M Stumvoll Journal: J Clin Endocrinol Metab Date: 2001-10 Impact factor: 5.958
Authors: Jia-Qi Li; Jie Chen; Nan-Nan Liu; Li Yang; Ying Zeng; Bin Wang; Xue-Rong Wang Journal: World J Gastroenterol Date: 2011-04-28 Impact factor: 5.742
Authors: Jie Chen; Nan-Nan Liu; Jia-Qi Li; Li Yang; Ying Zeng; Xiao-Mei Zhao; Lin-Lin Xu; Xuan Luo; Bin Wang; Xue-Rong Wang Journal: World J Gastroenterol Date: 2011-06-21 Impact factor: 5.742
Authors: K Almind; S K Frederiksen; D Bernal; T Hansen; L Ambye; S Urhammer; C T Ekstrøm; L Berglund; R Reneland; H Lithell; M F White; E Van Obberghen; O Pedersen Journal: Diabetologia Date: 1999-10 Impact factor: 10.122